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Background
Adenosine deaminase (ADA) deficiency is a disorder
where the accumulation of purine metabolites, which are
particularly toxic to lymphocytes, can lead to severe, life
threatening infections. In addition, ADA deficiency also
affects other tissues. Few reports describe the presence of
neutropenia in these patients, primarily in older patients
after hematopoietic stem cell transplantation (HSCT) or
gene therapy. We hypothesized that abnormal purine
metabolism could also affect granulopoiesis.
Objective
The objective of the study was to assess the frequency and
nature of neutropenia in patients with ADA deficiency in
the first 180 days of life.
Methods
This retrospective study analyzed all patients who were
diagnosed with ADA deficiency at the Hospital for Sick
Children between 1984 and 2012 and had at least one
documented complete blood count with differential in
the first 180 days of life.
A diagnosis of ADA deficiency was made when erythro-
cytes ADA enzyme activity was less than 1-2% of control
and/or demonstration of mutations in the ADA gene.
Neutropenia was defined as the absolute neutrophil
count of less than 6.0 x 109/L for ages ≤ 6 days, less than
1.5 x 109/L for ages 7-13 days, less than 1.0 x 109/L
for ages 14-89 days and less than 1.5 x 109/L for ages ≥
90 days. Patients were excluded if neutropenia was first
documented after chemotherapy for HSCT.
Results
Thirteen patients with ADA deficiency were included in
the study. Nine of the 13 patients had neutropenia that
was first documented within the first 180 days of life
(median age of first neutropenia 70 days, range
1-176 days). In 5 patients, the neutropenia was not present
on the initial blood count but developed over time. The
lowest neutrophil counts ranged from 0.11-1.08 x 109/L
(median 0.5 x 109/L). The neutropenia developed in
7 patients prior to the onset of cotrimoxazole or other
medications that commonly have myelosuppressive effects.
The neutropenia was not associated with infections
commonly causing neutropenia or with autoimmune
manifestations. Bone marrow examinations in 2 patients
with neutropenia were reported as normal. The neutrope-
nia improved spontaneously in 3 patients, while in
4 additional patients it resolved after initiation of PEG-
ADA replacement therapy or HSCT.
Conclusions
Neutropenia occurs commonly in patients with ADA
deficiency. Further studies are required to determine the
pathogenesis of the neutropenia in ADA deficiency.
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